Form 4: Zevra Therapeutics Executive Joshua Schafer Reports Stock Option Grant and RSU Vesting

CCO & EVP of Business Development at Zevra Therapeutics, Joshua Schafer, reports the acquisition of stock options and vesting of restricted stock units.

Summary

• Joshua Schafer, CCO & EVP of Business Development at Zevra Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• On January 30, 2025, Schafer was granted stock options to purchase 68,000 shares of Zevra Therapeutics common stock at a price of $8.02 per share.
• These options vest in four equal annual installments starting January 29, 2035, subject to continued service.
• Additionally, 35,333 restricted stock units (RSUs) vested and settled on January 31, 2025, resulting in the disposition of 35,333 shares.
• Schafer also acquired 34,000 restricted stock units on January 30, 2025, which will vest in three annual installments starting January 30, 2026.
• Following these transactions, Schafer directly owns 39,986 shares of common stock, 70,667 restricted stock units, and stock options for 68,000 shares.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing detailing stock option and RSU activity. It's neutral in tone and reflects standard compensation practices.

Positives

• The grant of stock options and RSUs to a key executive like Joshua Schafer aligns his interests with those of the shareholders.
• The vesting schedule of the options and RSUs incentivizes continued service and commitment to the company's long-term success.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the vesting schedules of the stock options and RSUs suggest an expectation of continued service and contribution from the reporting person.

Industry Context

Stock option and RSU grants are common practices in the pharmaceutical industry to incentivize executives and align their interests with shareholders. The vesting schedules are typical for retention purposes.

Comparison to Industry Standards

• Stock option grants and RSU awards are standard compensation practices in the biopharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Biogen routinely use similar equity-based compensation plans for their executives.
• Vesting schedules of four years for stock options and three years for RSUs are also common benchmarks in the industry.

Stakeholder Impact

• Shareholders may view the stock option and RSU grants as a positive sign, indicating that the company is incentivizing its executives to create long-term value.
• Employees may be motivated by the fact that executives are receiving equity-based compensation, aligning their interests with the company's success.

Key Dates